# Qualify one iPSC master cell bank once for many off-the-shelf cell products

Source: https://onco.cc/ideas/idea-reg-ipsc-master-bank-qualified-once/  
OnCo record `idea-reg-ipsc-master-bank-qualified-once` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cell therapies made from a single stem cell line could be produced in bulk. Regulators should let companies certify the parent cell line once rather than repeating it for every product.

## Summary

Induced pluripotent stem cell-derived CAR-NK and CAR-T products (Fate, Century, Sana, Shoreline and others) start from a clonal, gene-edited master cell bank that can in principle yield thousands of doses per run. Today each product's regulatory file repeats the characterisation of the bank (genomic stability, tumourigenicity, identity, adventitious agents). The proposal is a 'qualified master bank' status: a hypoimmune-edited iPSC bank characterised once to an agreed standard and cross-referenced by any product derived from it, with only the differentiation and CAR-specific data submitted per product.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Qualified-bank status cuts the CMC section of an iPSC-derived product IND by at least half and the time from candidate selection to first-in-human by a year, while enabling a cost of goods per dose below $5,000 at scale.
- Rationale: Drug master files for excipients and platform designations for vectors already allow shared, referenced qualification. iPSC banks are the most expensive, most repeated component of the allogeneic pipeline and their characterisation is product-independent.
- Proposed test: FDA and EMA pilot a master-bank designation with two or three developers, publish the characterisation standard, and compare CMC review questions and timelines against conventional iPSC product INDs.
- Maturity: early-clinical
- Actor: regulator

## Sources

- Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018): https://doi.org/10.1001/jamaoncol.2018.0977

## Connected records

- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [CAR-NK & CAR-macrophage](https://onco.cc/technologies/car-nk-macrophage/)
- companies: [Fate Therapeutics](https://onco.cc/companies/fate-therapeutics/), [Sana Biotechnology](https://onco.cc/companies/sana-biotechnology/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/)
- key papers: [Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy](https://onco.cc/key-papers/paper-hernandez-jama-oncol/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-ipsc-master-bank-qualified-once.json